Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401322 · ClinicalTrials.gov registry record · Phase 2
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01401322: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT01401322 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01401322, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Time-to-Progression (TTP)
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01401322
The ClinicalTrials.gov registry entry for NCT01401322 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT01401322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01401322 about?
NCT01401322 is a clinical study titled "Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia". Time-to-Progression (TTP)
What is the current status of trial NCT01401322?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2011-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01401322?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01401322?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.